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Abstract
Background: An increasing number of studies report associations between variation in DTNBP1, a top candidate gene in
schizophrenia, and both the clinical symptoms of the disorder and its cognitive deficits. DTNBP1 encodes dysbindin-1,
reduced levels of which have been found in synaptic fields of schizophrenia cases. This study determined whether such
synaptic reductions are isoform-specific.
Methodology/Principal Findings: Using Western blotting of tissue fractions, we first determined the synaptic localization of
the three major dysbindin-1 isoforms (A, B, and C). All three were concentrated in synaptosomes of multiple brain areas,
including auditory association cortices in the posterior half of the superior temporal gyrus (pSTG) and the hippocampal
formation (HF). Tests on the subsynaptic tissue fractions revealed that each isoform is predominantly, if not exclusively,
associated with synaptic vesicles (dysbindin-1B) or with postsynaptic densities (dysbindin-1A and -1C). Using Western
blotting on pSTG (n = 15) and HF (n = 15) synaptosomal fractions from schizophrenia cases and their matched controls, we
discovered that synaptic dysbindin-1 is reduced in an isoform-specific manner in schizophrenia without changes in levels of
synaptophysin or PSD-95. In pSTG, about 92% of the schizophrenia cases displayed synaptic dysbindin-1A reductions
averaging 48% (p = 0.0007) without alterations in other dysbindin-1 isoforms. In the HF, by contrast, schizophrenia cases
displayed normal levels of synaptic dysbindin-1A, but 67% showed synaptic reductions in dysbindin-1B averaging 33%
(p= 0.0256), while 80% showed synaptic reductions in dysbindin-1C averaging 35% (p= 0.0171).
Conclusions/Significance: Given the distinctive subsynaptic localization of dysbindin-1A, -1B, and -1C across brain regions,
the observed pSTG reductions in dysbindin-1A are postsynaptic and may promote dendritic spine loss with consequent
disruption of auditory information processing, while the noted HF reductions in dysbindin-1B and -1C are both presynaptic
and postsynaptic and could promote deficits in spatial working memory.
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Introduction
Among the many genes which may promote development of
schizophrenia, DTNBP1 (dystrobrevin binding protein 1) remains
among the top candidates [1,2] and is hence among the most
intensively investigated. Twenty studies on populations across the
globe report significant associations between schizophrenia and
one or more DTNBP1 SNPs and/or haplotypes (cf. [3–6]). An
increasing number of studies report that several of these DTNBP1
risk variants are associated with severity of the positive symptoms
(e.g., delusions and hallucinations) and especially the negative
symptoms (e.g., flattened affect and social withdrawal) of
schizophrenia [7–10]. Such genetic variants are also associated
with severity of cognitive deficits in this disorder [3,11–14].
Indeed, several DTNBP1 risk SNPs are significantly more common
in the subset of schizophrenia cases marked not only by earlier
adult onset and more chronic course, but by more prominent
positive and negative symptoms, as well as greater cognitive
deficits [15].
There is consequently escalating interest in understanding the
role of DTNBP1 variants and of its encoded protein in
pathophysiology of schizophrenia. That protein is commonly
known as dysbindin and more accurately as dysbindin-1 [5]. It is
the largest member of a protein family with three paralogs
(dysbindin-1, -2, and -3) encoded by different genes yet sharing
sequence homology in a region called the dysbindin domain [5].
Each paralog exists in multiple isoforms. Among the 16 splice
variants of DTNBP1 mRNA listed in the AceView database, there
are three reference variants (NM_032122, NM_183040, and
NM_183041). They appear to be the most commonly expressed
transcripts given the number of cDNA clones available for their
reconstruction. These three transcripts encode the isoforms we call
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dysbindin-1A, -1B and -1C (NP_115498, NP_898861, and
NP_898862, respectively, in NCBI Entrez Protein database [5]).
How DTNBP1 risk SNPs or haplotypes may affect dysbindin-1 is
still unknown, but it is known that levels of this protein are lower in
two brain areas dysfunctional in schizophrenia. A quantitative
immunohistochemical study on the hippocampal formation (HF)
found that more than 70% of the schizophrenia cases tested had
lower presynaptic levels of dysbindin-1 compared to matched
controls [16]. A more recent Western blotting study on whole-tissue
lysates of dorsolateral prefrontal cortex similarly found that more
than 70% of schizophrenia cases studied had lower levels of
dysbindin-1 than matched controls, but limited to dysbindin-1C [17].
These findings collectively suggest that dysbindin-1 reductions
in schizophrenia may be isoform specific reductions occurring in
synaptic tissue. To test that hypothesis, we conducted the first
Western blotting studies on synaptic dysbindin-1 in this disorder.
We specifically tested synaptosomal levels of its major isoforms in
the temporal lobe of schizophrenia cases compared to matched
controls and the subsynaptic localization of those isoforms to
interpret the results. The temporal lobe structures investigated
were the HF and the posterior half of the superior temporal gyrus
(pSTG). The latter consists primarily of auditory cortices: the
primary (or core) auditory cortex (Brodmann, BA, area 41), a
surrounding secondary auditory area (i.e., auditory belt, BA42),
and adjoining auditory parabelt on the lateral wall of the pSTG
(caudolateral BA 22) [18–21].
We focused on the HF and STG since they are among the most
profoundly affected brain areas in schizophrenia, displaying
diverse structural, chemical, and physiological abnormalities in
neuronal assemblies [21–24]. Such abnormalities in the STG are
well known to extend into the pSTG (cf. refs. [25–29]). These
abnormalities are of such magnitude in the HF and STG,
including primary and secondary auditory areas of the pSTG, that
macroscopic volume reductions occur there in schizophrenia (cf.
[21,24,29–32]) and are evident even at the time of diagnosis
[31,33,34]. The degree of tissue shrinkage is significantly
correlated with the degree of memory and executive function
deficits in the case of HF volume reductions [35–38] and with the
frequency and severity of auditory hallucinations in the case of
STG volume reductions [39–42].
Results
Dysbindin-1 distribution seen immunohistochemically
Immunohistochemistry with our PA3111 antibody [16,43]
(Figures 1B, C and 2), which recognizes all three major isoforms
of dysbindin-1, revealed that this protein is neuronal, not glial. In
the pSTG, the protein was expressed in neurons and their cell
nuclei in layers 2–6, but was highest in layers 2 and 3 (Figure 2A).
In pyramidal cells of layer 3, the immunoreactivity spread into
basal and especially apical dendrites (Figure 2B). Diffuse
immunoreactivity in synaptic tissue between neuronal cell bodies
(i.e., neuropil) was higher in layers 1–3 than in deeper layers
(Figures 2A and 2B). In the HF of the same cases fixed in the same
manner and cut at the same thickness, immunoreactivity in
neuronal cell bodies, primary dendrites, and neuropil was
distinctly higher than in the pSTG even when sections from these
two areas were reacted together in the same experiment (cf.
Figures 2A and 2B with 2C and 2D). This was most notable in
CA3 and the dentate gryus (DG), where very high levels of
dysbindin-1 occurred in large neurons (pyramidal cells in CA3 and
hilar polymorph cells in the DG) and in synaptically dense layers of
neuropil (strata oriens and radiatum in CA3 and the inner
molecular layer in the DG: cf. Figures 1C and 2C and 2D (see also
[5,16,43]). In both pSTG and HF, dysbindin-1 was also expressed
at lower levels in at least a subset of smaller neurons (Figure 2B),
probably interneurons, in both the pSTG and HF.
Dysbindin-1 isoforms in synaptosomes
As noted earlier, there are three major dysbindin-1 isoforms [5].
Figure 3A indicates the length and composition of these isoforms.
All have a coiled coil domain (CCD, divided into helixes H1 and
H2) important for certain protein-protein interactions. Isoform A
(,50 kDa: 351 amino acids [aa] in humans, 352 aa in mice) is full-
length dysbindin-1 and has a PEST domain at its C-terminus.
Isoform B (,37 kDa: 303 aa in humans, not present in mice)
differs from isoform A only in its C-terminus, which is shorter and
lacks a PEST domain. Isoform C (,33 kDa: 270 aa in humans,
271 aa in mice) differs from isoform A only in the absence of the
N-terminus region found in the other isoforms in front of the
CCD.
The specificity of our four dysbindin-1 antibodies (Oxford
Hdys764, Oxford PA3111, UPenn 329, and UPenn 331:
Figure 3B) was confirmed in tests using both positive and negative
controls (see Text S1 and Figures S1 and S2). These tests also
showed that PA3111and UPenn 331 have complementary abilities
detecting dysbindin-1 isoforms (Table 1). PA3111 has a high
affinity for both dysbindin-1A and -1C but a lesser affinity for
dysbindin-1B, whereas UPenn 331 has a high affinity for
dysbindin-1B but low affinity for dysbindin-1A and does not
recognize dysbindin-1C (Figure S1). The present study is thus
based on findings with those two antibodies. Hdys764 and UPenn
329 were not used for final testing since they yield reliable signals
in postmortem tissue only at higher concentrations and hence with
higher levels of background reactivity.
Consistent with our earlier fractionation and immunohisto-
chemical studies on dysbindin-1 in mouse and human brain tissue
[43], all three of its major isoforms were concentrated in synaptic
tissue though high concentrations of isoform B were also found in
cell nuclei (Figure 4A). This was seen at the level of synaptosomes
in all brain areas studied (anterior cingulate cortex, dorsolateral
prefrontal cortex, HF, pSTG, and caudate nucleus), especially
when using UPenn 331 to detect dysbindin-1B (Figure 4B). It was
found, however, that the relative amounts of the isoforms differed
between and within brain areas. Synaptosomal dysbindin-1A was
clearly less concentrated in the pSTG and HF than in the three
other brain areas studied (cf. Figures 4A and 4B) as confirmed
when levels of actin-normalized data were compared across brain
areas. In the pSTG and HF, dysbindin-1A was also much less
abundant than dysbindin-1C: 3.1 times less abundant in the pSTG
and 6.4 times less abundant in the HF as assessed with PA3111
(Figure 4C). Levels of dysbindin-1B relative to other dysbindin-1
isoforms could not be determined, because none of our antibodies
had high affinity for all three isoforms. While the pSTG and HF in
normal cases did not differ in levels of dysbindin-1A, the mean
levels of dysbindin-1B and -1C were higher in the HF than in the
pSTG. As shown in Figure 4C, the differences approached
significance in the case of isoform B (t =21.97, p = 0.059) and
were highly significant in the case of isoform C (t =24.31,
p = 0.0002). Such differences may explain the higher levels of
dysbindin-1 immunoreactivity in dendritic stalks and neuropil of
the HF compared to the pSTG (see Figure 2).
Distribution of dysbindin-1 isoforms in subsynaptic tissue
fractions
Each dysbindin-1 isoform was found to have a unique
distribution pattern in synaptic tissue, one found in all tissues
studied (anterior cingulate and dorsolateral prefrontal cortices,
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pSTG, HF, and caudate nucleus). This is shown for the isoforms in
the normal human HF in Figure 5A, which presents Western
blotting results on synaptosomes and subsynaptic fractions derived
from them using a reliable fractionation method validated with
electron microscopy and diverse pre- and post-synaptic markers by
Phillips et al. [44,45] in experimental animals and by our group in
mouse and human brain tissue [43,46,47]. To show that the
synaptic fractionation was successful, we include results with the
markers of synaptic vesicles (synaptophysin) and postsynaptic
densities (PSD-95).
Dysbindin-1A was undetectable in synaptic vesicle (SV)
fractions, but was quite abundant in postsynaptic density (PSD)
fractions. Conversely, dysbindin-1B was highly abundant in SV
fractions, but virtually undetectable in PSD fractions. Dysbindin-
1C was present to a small degree in the SV fractions of most cases,
but was far more abundant in PSD fractions. Minor amounts of
dysbindin-1A and -1C were detected in presynaptic membrane
(PrS) fractions, but this may simply reflect incomplete separation of
these soluble proteins from PSD fractions. A schematic summary
of these findings is given in Figure 5B. The distribution pattern of
dysbindin-1 isoforms in synapses was the same in normal and
schizophrenia cases.
Synaptosomal dysbindin-1 isoforms in schizophrenia
cases vs. controls
Isoform-specific dysbindin-1 reductions occurred in synapto-
somes of the schizophrenia cases, but the specific isoforms affected
differed in the two brain areas studied. Figures 6A and 7A show
representative Western blots of synaptosomal dysbindin-1 in the
pSTG and HF of schizophrenia cases and their matched controls.
Below the blots are graphs for each dysbindin-1 isoform. Each bar
in these graphs indicates the ratio of a b-actin normalized isoform
in a schizophrenia case compared to that in its matched control
(i.e., the ratio for one case-control pair). The ratios are log2
transformed so that zero values indicate no differences between
cases and controls, negative values indicate reduced dysbindin-1 in
a schizophrenia case, and positive values indicate the reverse.
In pSTG (Figure 6), synaptosomal dysbindin-1A in pSTG was
reduced in 12 of the 13 case-control pairs (92.30%) by an average
of 47.73% (W =287.00, p = 0.0007). Cases and controls did not
Figure 1. Temporal lobe areas studied: posterior superior temporal gyrus (pSTG) and intermediate rostrocaudal hippocampal
formation (HF). A: Location of those structures mapped on a template adapted from Nieuwenhuys et al. [85]. B and C: Tissue sections from pSTG
and HF, respectively, reacted immunohistochemically for dysbindin-1 with antibody PA3111. pSTG samples included BA 22 and 42. The cellular
localization of dysbindin-1 in the sampled areas is shown in Figure 2.
doi:10.1371/journal.pone.0016886.g001
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differ significantly in synaptosomal levels of dysbindin-1B or 1C in
this brain area.
In the HF (Figure 7), the results were opposite those in pSTG.
No significant case-control differences were found in the HF for
synaptosomal dysbindin-1A, but synaptosomal dysbindin-1B was
reduced in 10 of the 15 case-control pairs (66.66%) by an average
of 33.06% (W =278.00, p = 0.0256), and synaptosomal dysbin-
din-1C was reduced in 12 of those 15 pairs (80.0%) by an average
of 34.77% (W =233.50, p = 0.0171). No significant correlations
were found between the case-control ratios for dysbindin-1B and -
1C.
Consideration of potential confounding variables
The observed reductions in synaptosomal dysbindin-1 isoforms
were not attributable to non-diagnostic variables (i.e., age, sex,
PMI, pH), none of which were significantly correlated with levels
of the dysbindin-1 isoforms tested. This is consistent with the
design of this study. Cases and controls were matched for age
(within 5 years), sex, and hemisphere studied. While availability of
frozen tissue necessitated using largely different sets of cases for
samples of the pSTG and HF, the normal and schizophrenia cases
within and between these sets did not differ significantly in age,
PMI, or brain tissue pH. In both sets of cases, the average PMIs
were fairly short (9.5–11.0 h), and the average pHs were close to
neutral (6.5–6.6) (Table 2). The fact that the same number of
bands was seen in Western blots of the schizophrenia cases argues
against lesser integrity of dysbindin-1 in those cases compared to
controls, consistent with reports that many brain proteins remain
intact under cool conditions within the PMIs of our cases (e.g.,
[48]).
None of the subjects had histories of neurological or psychiatric
conditions other than schizophrenia, and none displayed neuro-
pathological abnormalities such as gross cell loss, infarcts, or
unusually high densities of amyloid plaques, neurofibrillary
tangles, or Lewy bodies. Nor were significant correlations found
between antipsychotic dosages of our schizophrenia cases
(expressed in chlorpromazine equivalents) a month prior to death
and dysbindin-1 isoform levels, a finding in accordance with an
earlier study by our group [16]. This is consistent with studies
demonstrating that chronic haloperidol administration in mice has
no significant effect on dysbindin-1 gene [49] or protein [16]
expression.
Finally, our findings were not attributable to loss of synapses in
the schizophrenia cases for three reasons. First, protein assay data
on all synaptosomal samples were used to load the same amount of
synaptic protein in the Western blots. Second, to correct for any
loading errors, the dysbindin-1 isoforms levels analyzed were those
normalized to synaptosomal levels of b-actin in each sample.
Third, the synaptosomal fractions of our normal and schizophre-
nia cases showed no significant differences in either the synaptic
vesicle marker synaptophysin (p.0.5) or the postsynaptic marker
PSD-95 (p.0.9). The lack of differences between normal and
Figure 2. Distribution of dysbindin-1 in normal human pSTG and HF as seen immunohistochemically with PA3111. A: While higher
neuropil concentrations of the protein are evident in the HF, dysbindin-1 is also present in neuropil of the pSTG, most notably in superficial layers 1–
3. B: Higher magnification view of boxed area A, which reveals dysbindin-1 not only in neurons of Brodmann area (BA) 42, but in pyramidal cell apical
and basal dendrites such as those indicated by an arrow and arrow head, respectively. Inset shows higher magnification of boxed field. The smaller,
less immunoreactive cells may be interneurons. Higher dysbindin-1 levels are seen in pyramidal cells of hippocampal field CA3 (C) and in polymorph
cells of the dentate gyrus (DG) (D), including dendrites (arrowed) and axon terminal fields of those cells. l, o, and p= strata lucidum, oriens, and
pyramidal of CA3, respectively; g, h, iml = granule cell, hilus, and inner molecular layer of the DG, respectively.
doi:10.1371/journal.pone.0016886.g002
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schizophrenia cases in synaptophysin was observed previously in
our quantitative immunohistochemical study of dysbindin-1 in the
HF [16].
Discussion
The present study demonstrates (1) that the three major
dysbindin-1 isoforms are synaptically located in the human brain,
(2) that they are differentially distributed in synaptic compart-
ments, (3) that one or more of these pre- and/or post-synaptically
localized isoforms are significantly reduced in synaptosomes of the
pSTG and HF in schizophrenia without loss of synaptic vesicle or
PSD markers. Each isoform was found to be associated primarily
(if not exclusively) with either SVs or PSDs across brain areas in
both normal and schizophrenia cases with dysbindin-1A limited to
PSD fractions, dysbindin-1B to synaptic vesicle fractions, and
dysbindin-1C primarily to PSD fractions. Dysbindin-1 isoform
reductions observed in synaptosomes of schizophrenia cases thus
indicate the subsynaptic compartments where those reductions
occurred. We focus here on the implications of such reductions in
the pSTG (BA 42 and caudal BA 22) and HF for the pathology
and cognitive features of schizophrenia.
Auditory cortices
In the pSTG, which consists largely of the auditory cortices
[18–21], about 92% of our schizophrenia cases showed dysbindin-
1A reductions averaging about 48% compared to their matched
controls. This highly significant reduction (p = 0.0007) occurred
without significant changes in levels of synaptic dysbindin-1B or
-1C. Given our finding that synaptic dysbindin-1A is essentially
limited to PSD fractions, these results indicate that an isoform-
specific decrease in postsynaptic dysbindin-1 in auditory cortices
occurs in schizophrenia. Our data do not establish the type(s) of
neuron in which this decrease occurs, but the type likely to be
affected the most are those expressing the highest levels of cellular
and dendritic dysbindin-1, namely the pyramidal cells in layer III.
They are characterized not only by their cell body shape, but also
by their dendritic spines and axon collaterals terminating locally
Figure 3. Major dysbindin-1 isoforms in humans and the immunogens used to generate antibodies to them by our research group.
A: Schematic of the primary structure and protein segments of the three major dysbindin-1 isoforms in humans as characterized by Talbot et al. [5].
The numbers below isoforms designate amino acid (aa) location starting at the N-terminus. CCD= coiled coil domain composed of helices 1 and 2 (H1
and H2) separated by a stutter region (SR), CTR= carboxy terminus region, DD= the dysbindin domain, LZM= leucine zipper motif (LZM), NTR= amino
terminus region, PD=PEST domain, X1 and X2 are uncharacterized regions. B: Location of immunogens for PA3111A, UPenn 331, and UPenn 329
shown on dysbindin-1A. Dysbindin-1A is 351 aa in humans, but 352 aa in mice.
doi:10.1371/journal.pone.0016886.g003
Table 1. Relative isoform affinity of dysbindin-1 antibodies
tested.
Antibody Dysbindin-1A Dysbindin-1B Dysbindin-1C
Hdys764 ++++ — ++++
PA3111 ++++ +/++ ++++
UPenn 329 ++++ , +++
UPenn 331 + ++++ —
Antibody affinities are based on Western blotting tests of whole tissue lysates
from normal human brain tissue (caudate nucleus, dorsolateral prefrontal
cortex, HF, and pSTG). Results of such tests on the caudate nucleus and pSTG
are described in Text S1 and illustrated in Supplementary Figure 1.
doi:10.1371/journal.pone.0016886.t001
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and in other auditory cortices (see [27]). In schizophrenia, Sweet
and his colleagues [27] report that deep layer III of the primary
and secondary auditory cortices in schizophrenia cases display
dendritic spine density reductions of 27.2% and 22.2%, respec-
tively. This was correlated with decreased densities of axon
terminals in primary, but not in the secondary auditory cortex
[26]. In light of the relevant literature, Sweet et al. [27] proposed
that reduced excitatory afferent input on the dendritic spines of
deep layer III pyramidal cells in auditory cortices may account for
their decreased density in schizophrenia.
Decreased postsynaptic dysbindin-1A may be another factor
promoting dendritic spine loss in auditory cortices of schizophrenia
cases, potentially explaining why that occurs in secondary auditory
cortex (BA 42) without axon terminal loss there. Reduced spine density
is observed in mice with a cerebrocortical knockout of the gene
encoding NMDA receptor subunit 1 [50], mRNA expression of which
is reduced in sandy mice lacking dysbindin-1 due to a deletion
mutation in Dtnbp1 [51]. Spine density may also be affected by
dysbindin-1 reductions in another way. Two proteins binding
dysbindin-1 directly (rab11A [52]) or indirectly via pallidin (syntaxin-
13, cf. [53,54]) are known components of recycling endosomes whose
membranes are required for growth and maintenance of dendritic
spines [55]. These are highly labile structures [56] receiving most of
the excitatory input on spiny neurons in the brain [57].
By lowering NMDA receptor densities or by disrupting
endosomal trafficking in dendritic spines as recently postulated
Figure 4. Concentration of dysbindin-1 isoforms A–C in synaptic tissue and relative synaptosomal levels of the isoforms in Western
blots (WB) of normal human cerebral cortex and HF. A: Relative concentrations of the isoforms seen in whole cell lysates (Lys) and cell
fractions: cell nuclei (Nuc), synaptosomes (Syn), synaptic vesicles (SV), and postsynaptic densities (PSD) using PA3111. While the samples were from
the anterior cingulate cortex (AC), the same distribution pattern was seen in the pSTG and HF, except for lower synaptosomal dysbindin-1A. Bands
marked to the left by dots mark likely dysbindin-1 degradation products in SV and PSD fractions. B: Relative concentrations of the dysbindin-1
isoforms in synaptosomes in the pSTG and HF using PA3111 for isoforms 1A and 1C and UPenn 331 for isoform 1B. The higher signal for dysbindin-1B
compared to that seen in A probably reflects the much higher affinity of UPenn 331 than PA3111 for this isoform (Figure S1). C: Relative levels of
synaptosomal dysbindin-1 isoforms in pSTG and HF compared using normalized PA3111 and UPenn 331 data for all normal cases studied (13 for
pSTG, 15 for HF). Dysbindin-1C concentrations in the HF were significantly greater than in the pSTG (p = 0.0002, marked by an asterisk [*]). OD=
b-actin normalized optical density of bands in Western blots.
doi:10.1371/journal.pone.0016886.g004
Figure 5. Subsynaptic localization of dysbindin-1 isoforms. A: Western blotting results on synaptosomal (Syn), synaptic vesicle (SV),
presynaptic membrane (PrS), and postsynaptic density (PSD) fractions of the normal HF from three control cases (1–3) in this study. Successful
synaptic fractionation was confirmed with synaptophysin as a marker for synaptic vesicles and PSD-95 as a marker for the PSD. No selective molecular
marker is available for the PrS fraction, including syntaxin-1 since this proves to be ubiquitously distributed on subcellular membranes. b-actin served
as the loading control. The blots were probed with PA3111 (1:1000) for dysbindin-1A and -1C and with UPenn 331 (1:5000) for dysbindin-1B. In
synaptosomes, dysbindin-1A and -1C were found to be predominantly PSD proteins, while dysbindin-1B was found to be predominantly a synaptic
vesicle-associated protein. MW=molecular weight marker position. B: Diagram of pre- and/or post-synaptic location of dysbindin-1 isoforms
consistent with the Western blotting results just shown and with dysbindin-1 immunohistochemical findings at the electron microscopic level by
Talbot et al. [43].
doi:10.1371/journal.pone.0016886.g005
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to occur in schizophrenia [58], postsynaptic dysbindin-1A
reductions may impair excitatory transmission among auditory
cortices and consequently promote dysfunctional connectivity
among cerebrocortical areas in schizophrenia [59], which is
thought to account for reduced gamma band synchrony in that
disorder [60]. It is thus possible that postsynaptic dysbindin-1A
reduction in auditory cortices in schizophrenia contributes to the
many abnormalities in auditory information processing in the
disorder [61,62], including auditory hallucinations whose frequen-
cy and severity are significantly associated with volume reductions
of the STG [39–42]. While we failed to detect PSD-95 reductions
expected with spine loss in pSTG samples of schizophrenia cases,
such a loss may have been masked by the inclusion of tissue
beyond areas of the auditory cortices where spine loss has been
shown in such cases (i.e., layer III of Brodmann areas 41 and 42
[27]).
Hippocampal formation
In contrast to the pSTG, the HF in our schizophrenia cases
showed normal levels of synaptic dysbindin-1A but reduced levels
of synaptic dysbindin-1B and -1C. 67% of the cases showed
decreased synaptosomal dysbindin-1B averaging 33% of controls
(p = 0.026), while 80% showed decreased synaptosomal dysbindin-
1C averaging 35% of controls (p = 0.017). It is unclear if the pair-
wise (i.e., case-control) reductions in these two isoforms result from
the decreased DTNBP1 gene expression found in this brain area of
schizophrenia cases by Weickert et al. [63]. Decreased dysbindin-
1C levels have been found in the dorsolateral prefrontal cortex
without altered DTNBP1 gene expression [17]. An alternative
possibility is suggested by the fact that the pair-wise reductions in
dysbindin-1B and -1C in the HF were not correlated with each
other. This may reflect differential posttranslational regulation of
the two isoforms, perhaps due to the E3 ubiquitin ligase TRIM32,
a dysbindin-1 binding partner known to ubiquitinate it [64]. In
synaptosomes from the same HF samples used in the present
study, we have found that levels of TRIM32 are inversely and
significantly correlated with levels of dysbindin-1C, but not with
levels of dysbindin-1B [65].
Given that synaptic dysbindin-1B is limited to SV tissue
fractions, its reduction in the HF indicates a presynaptic decrease
in HF dysbindin-1. This confirms our earlier immunohistochem-
ical report [16] that the HF in schizophrenia suffers a reduction in
presynaptic dysbindin-1. Indeed, the sample of schizophrenia
cases in the present work is the third displaying this phenomenon,
the previous two being another sample from the University of
Pennsylvania and one from the Stanley Foundation.
Our previous immunohistochemical study [16] showed that the
presynaptic dysbindin-1 reductions occur in axon terminals of
intrinsic glutamatergic pathways of the HF, where our later
fractionation and electron microscopic work found dysbindin-1 to
be closely associated with synaptic vesicles [43]. Several groups
have shown that reduced presynaptic dysbindin-1 impairs
glutamatergic transmission [66–69].
HF reduction in synaptic dysbindin-1C could reflect decreases
in both pre- and post-synaptic levels of the protein, but the latter
would be predominant given that the bulk of this isoform is found
in PSD fractions of synaptosomes. Such a postsynaptic effect was
not detected in our earlier immunohistochemical report [16],
which could not distinguish between dysbindin-1 in synaptic vs.
non-synaptic portions of dendrites. At the electron microscopic
level, we later localized dysbindin-1 in thick (i.e. glutamatergic)
PSDs of dendritic spines in the HF of mice and macaques using
electron microscopy [43]. Decreased dendritic spine density in
much of the HF is suggested in schizophrenia by decreased
expression of spinophilin mRNA [70] and confirmed in Golgi
studies on the subiculum [71]. Reduced dysbindin-1C may
contribute to spine loss in the same manner proposed above for
reduced dysbindin-1A in auditory cortices.
By affecting pre- and post-synaptic aspects of glutamatergic
transmission, the observed reductions in dysbindin-1 isoforms in
the HF of schizophrenia cases could disrupt information
processing in that structure and thus impair its cognitive functions.
This is supported by studies on dysbindin-1 mutant (i.e., sandy)
mice whose behavioral abnormalities resemble those of rodents
with HF lesions [72]. The abnormalities include diverse cognitive
deficits [reviewed by ref. 73], among which are spatial memory
deficits [72,74] common in schizophrenia [75,76]. Since cognitive
deficits form a core feature of that disorder [75,77–79], the
isoform-specific dysbindin-1 reductions we have found in schizo-
phrenia may contribute to the clinical expression of schizophrenia.
Materials and Methods
Ethics statement
The present research on archived tissue samples taken at
autopsy was approved by an Institutional Review Board at the
University of Pennsylvania. Autopsy consent from next-of-kin or
legal guardian was obtained in all cases. For most cases, consent
was granted in writing before death and always confirmed after
death. To keep postmortem delays to a minimum when written
consent had not been obtained before death, verbal consent was
obtained as witnessed by a third party and documented by the
physician making the request. Written records of the consent for
autopsy were archived. These procedures for written and verbal
consent are standard medical practice in the U.S.A.
Research design and subjects
A matched-pairs design was used in which each schizophrenia
case was matched to a normal control in sex, age (within 5 y), and
hemisphere sampled. The schizophrenia cases had participated in
a longitudinal study of prospectively diagnosed subjects that
conducted by the Schizophrenia Research Center at that
university [80]. They met the diagnostic criteria for schizophrenia
in DSM-IV (Diagnostic and Statistical Manual of Mental
Disorders, 4th ed. [81]) as determined in consensus conferences
after review of medical records, direct clinical assessments, and
Figure 6. Relative levels of dysbindin-1A, -1B, and 1C in synaptosomal fractions of the pSTG from schizophrenia cases compared to
their matched normal controls based on Western blotting results. A: Representative immunoblots on case-control pairs 1–7. Essentially the
same results were obtained for dysbindin-1A with both antibodies against its CTR (i.e., Hdys764 [1:800] and PA3111 [1:1000]). Optical density readings
confirmed that the bands in these Western blots were not close to saturation. B–D: Plotting of b-actin normalized data on dysbindin-1 isoforms for all
13 case-control pairs using PA3111 (1:1000) or UPenn 331 (1:5000). Each bar in these graphs gives the ratio of a dysbindin-1 isoform in a
schizophrenia (Sz) case to that in its matched normal (N) control. The Sz/N ratios were log2 transformed so that negative values signify less dysbindin-
1 isoform in the Sz case while positive values signify more of the isoform in the Sz case. Data for each Sz/N pair are not arranged according to the
order of pairs shown in the Western blots, but simply in order of their ratios from maximum negative to maximum positive values. All 13 case-control
pairs were used for statistical analyses on the three dysbindin-1 isoforms. Only dysbindin-1A showed significant differences between Sz cases and
their matched controls (p = 0.0007). MW=molecular weight marker position.
doi:10.1371/journal.pone.0016886.g006
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interviews of care providers. None of the cases had alternate or
ambiguous DSM-IV diagnoses nor a history of substance abuse,
neurological disorders (e.g., Alzheimer’s disease, epilepsy, and
Parkinson’s disease), or acute neurological insults (anoxia, strokes,
traumatic brain injury). Neither the controls nor schizophrenia
cases were on ventilators near time of death.
Tissue collection
After death, cases were stored at 2–4uC until transport to the
University of Pennsylvania, where all autopsies were performed.
Upon sagittal bisection, a hemispheres from each case was cut into
coronal slabs, which were frozen overnight at 280uC and then
sealed in plastic bags for long-term storage at 280uC. The pSTG
and HF were later dissected from these coronal slabs, as were the
anterior cingulate gyrus, dorsolateral prefrontal cortex, and
caudate nucleus used for comparative purposes and for antibody
testing.
Due to constraints imposed by frozen tissue availability, the
subjects sampled for study of the pSTG (n = 26) were largely
different than those sampled for study of the HF (n = 30). Tissue
was specifically collected from BA 42 and caudal BA 22 in the
pSTG and from intermediate rostrocaudal levels of the HF
(dentate gyrus + hippocampal fields CA1-3 + subiculum) located as
depicted in Figure 1. A summary of demographic and autopsy
information on the two sets of cases studied is given in Table 2.
The additional tissue taken from the anterior cingulate gyrus
(n = 5), dorsolateral prefrontal cortex (n = 5) and the caudate
nucleus (n = 4) for comparative purposes and antibody testing
came from the control cases sampled for the pSTG or HF.
Neuropathological assessment
The pSTG and HF were dissected at autopsy from the
hemisphere not reserved for fresh freezing. This tissue was fixed
in neutral-buffered formalin for 12–24 h, embedded in paraffin,
and sectioned coronally at 6 mm. Sections were stained with
hematoxylin and eosin to detect cell loss and infarcts or were
reacted immunohistochemically (see below) for amyloid plaques,
neurofibrillary tangles, or Lewy bodies with antibody bA42332
(1:8000) to b-amyloid 1–42 [82], AT8 (1:1000) to phosphorylated
tau (Thermo Scientific, Rockford IL, USA), Ub-1 (1:400) to
ubiquitin (Invitrogen 13–1600, Camarillo, CA, USA), or LB509
(1:1000) to a-synuclein (Abcam ab27766, Cambridge, MA). After
gross examination at autopsy and microscopic study of histological
and immunohistochemical preparations, cases were excluded if
they showed evidence of infarcts, tumors, gross cell loss, or
densities of plaques, tangles, or Lewy bodies abnormal for the age
of the individuals.
Dysbindin-1 antibodies
Four affinity-purified, polyclonal rabbit antibodies against
dysbindin-1 were used: Oxford Hdys764, Oxford PA3111, UPenn
329, and UPenn 331 (protein concentrations = 1.1, 0.1, 0.2, and
1.4 mg/ml, respectively). The Oxford antibodies were generated
in Dr. Derek Blake’s laboratory at the University of Oxford as
described earlier [43]. Hdys 764 was raised against amino acids
(aa) 198–351 of human dysbindin-1A (NCBI accession number
NP_115498). PA3111 was raised against aa 196–352 of mouse
dysbindin-1A (NP_080048). UPenn 329 was generated for Drs.
Talbot and Louneva at the University of Pennsylvania by Sigma
Genosys (The Woodlands, TX, USA) against a synthetic peptide
consisting of GGESPVVQSDEEEV ( = aa 313–326 in the C-
terminus of human dysbindin-1A). UPenn 331 was also generated
by Sigma Genosys against a synthetic peptide consisting of
SDKSREAKVKSKPR ( = aa 24–37 in the N-terminus of human
dysbindin-1A). The aa sequences used as immunogens for UPenn
329 and UPenn 331 share no significant sequence homology with
any known proteins other than dysbindin-1 isoforms. Results of
specificity tests on these antibodies are detailed in the Text S1 and
Figures S1 and S2.
Immunohistochemistry
To determine the normal localization of dysbindin-1 in the
human HF and pSTG, 6 mm sections from 9 control cases were
reacted immunohistochemically with the antibody PA3111 (1:300)
using the avidin-biotin-peroxidase protocol of Talbot et al. [16],
which may be summarized as follows. Formalin-fixed, paraffin-
Figure 7. Relative levels of dysbindin-1A, -1B, and 1C in synaptosomal fractions of the HF from schizophrenia cases compared to
their matched normal controls based on Western blotting results. A: Representative immunoblots on case-control pairs 1–7. Optical density
readings confirmed that the bands in these Western blots were not close to saturation. B–D: Plotting of the b-actin normalized data on dysbindin-1A,
-1B, and -1C for the 14–15 case-control pairs. Further explanation of the graphs is given in the caption to Figure 6. Significant differences were found
for dysbindin-1B (p = 0.030) and -1C (p = 0.019). PA3111 was used at 1:1000, UPenn 331 at 1:5000. {Dysbindin-1C analyses omitted one case-control
pair since the value for the control case was two SDs below the mean for the other controls. All 15 case-control pairs were used for the statistical
analyses on dysbindin-1A and -1B. MW=molecular weight marker position.
doi:10.1371/journal.pone.0016886.g007
Table 2. Demographic and autopsy data on cases studied.
Variable pSTG HF
Control Schizophrenia Control Schizophrenia
Number of Cases 13 13 15 15
Males/Females 4/9 4/9 8/7 8/7
Caucasians/African-Americans 10/3 13/0 12/3 15/0
Mean Age 6 SD (y) 79.1767.60 80.065.79 80.2069.37 81.3366.94
Hemisphere Sampled (L/R) 7/6 7/6 8/7 8/7
Mean PMI 6 SD (h) 9.5164.62 10.9263.16 9.6067.10 11.0364.08
Mean Brain Tissue pH 6 SD 6.5860.39 6.6060.16 6.5160.47 6.5060.27
doi:10.1371/journal.pone.0016886.t002
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embedded pSTG and HF tissue was sectioned at 6 mm, mounted
on glass slides, and air-dried. After de-waxing, tissue sections were
quenched for endogenous peroxidase activity and then subjected
to heat-induced epitope retrieval in 1 mM EDTA in 0.1 M Tris
buffer (pH 8.0). Following cooling and rinsing between steps, the
sections were incubated in primary antibody overnight at 4uC,
then incubated in biotinylated secondary antibody for 1 h at room
temperature, and subsequently treated with an avidin-biotin-
peroxidase complex for 1 h before reaction with a diaminobenzi-
dine (DAB) - hydrogen peroxide solution for 10 min. To visualize
dysbindin-1 in human pSTG and HF, 6 mm coronal sections from
9 normal cases were reacted as just described with PA3111 (1:300)
validated in previous studies [5,16,17,43] followed by light silver
intensification of the DAB reaction product as detailed elsewhere
[16]. No signal amplification was used in screening cases
immunohistochemically for neuropathological conditions in the
pSTG and HF with the antibodies for b-amyloid, tau, a-synuclein,
and ubiquitin noted above (see Neuropathological Assessment).
Preparation of tissue lysates, synaptosomes, and
subsynaptic fractions
Whole-tissue lysates for antibody testing were prepared with 0.3 g
of fresh frozen tissue from normal humans by homogenization in
RIPA buffer (Sigma Aldrich, St. Louis, MO, USA, R0278) with a
protease inhibitor cocktail (Sigma Aldrich P8340) and 2 mM EDTA.
The lysate was then centrifuged at 15,000 g for 5 min at 4uC, and
the supernatant collected for storage at 280uC. Nuclear extracts
were prepared with the NXTRACT CelLytic NuCLEAR extrac-
tion kit (Sigma Aldrich) per the manufacturer’s instructions.
Synaptosomes were obtained using a method based on Phillips
et al. [44,45]. For each case, 0.5 g fresh frozen tissue was
homogenized in a sucrose solution (0.32 mol/L sucrose,
0.1 mmol/L CaCl2, 1 mmol/L MgCl2) containing a protease
inhibitor cocktail (P8340, Sigma Aldrich). The homogenate was
brought to a final sucrose concentration of 1.25 mol/L by adding
2 mol/L sucrose and 0.1 mmol/L CaCl2. After being overlaid
with 1.0 mol/L sucrose and 0.1 mmol/L CaCl2, the homogenate
was centrifuged at 100,000 g for 3 h at 4uC. The synaptosomal
(Syn) fraction, which forms a band at the 1.25/1.0 mol/L sucrose
interface, was collected and stored at 280uC for further
fractionation or Western blotting. For the latter, 500 ml of the
collected Syn material was washed twice in 0.1 mmol/L CaCl2
and stored in Laemmli loading buffer.
Subsynaptic fractions of synaptosomes were obtained using the
method of Phillips et al. [44,45] as adapted by Louneva et al. [46].
Synaptosomes from normal humans were accordingly washed
twice in 0.1 mmol/L CaCl2 and then pelleted at 40,000 g. The
pellets were solubilized in 20 mmol/L Tris-HCl, pH 6.0, 1%
Triton X-100, and 0.1 mmol/L CaCl2, incubated on ice for
30 min, and centrifuged at 40,000 g. The supernatant is the
synaptic vesicle (SV) fraction. The remaining pellet contains the
synaptic junction consisting of pre- and post-synaptic membranes
with the PSD. This pellet was solubilized in 20 mmol/L Tris-HCl,
pH 8.0, 1% Triton X-100, and 0.1 mmol/L CaCl2, then
incubated on ice for 30 min and centrifuged at 40,000 g. The
resulting supernatant contains the PrS fraction, while the pellet
contains the PSD fraction. SV and PrS fractions were acetone
precipitated. All fractions were dissolved in 5% SDS. Protein
concentration was determined by the BCA method (Pierce
Chemical, Rockford, IL, USA).
Western blotting
Synaptosomal samples were denatured in Laemmli loading
buffer. After 5 min of boiling, the denatured samples were
centrifuged at 10,000 g for 5 min. Each lane was loaded with
20 mg of total protein, because pilot tests on our samples showed
that the ECL Plus chemiluminescence system (GE Healthcare,
Waukesha, WI) used in this study detects dysbindin-1 isoforms
reliably with that amount of protein. While two blots were needed
to accommodate all normal and schizophrenia samples from one
brain area, samples from any one matched pair of control and
psychiatric cases were run in adjoining lanes on the same blot, and
all blots for samples from any one brain area were imaged on the
same film. All samples were run at least twice in separate
replication experiments.
Proteins were separated by SDS-polyacrylamide gel electro-
phoresis on precast 12% Tris-glycine 1.5 mm gels (Invitrogen
Novex, Carlsbad, CA, USA) and thereafter transferred onto a
polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA,
USA) using a Novex XCell II Blot Module at 34 V for 80 min.
Membranes were blocked for 1 h with 5% milk and incubated
overnight at 4uC with primary antibody diluted in Tris-buffered
saline with a final concentration of 3% milk and 0.1% Tween-20.
Primary antibodies were used at dilutions that allowed detection
of their targets in a linear quantitative range: b-actin (Sigma
Aldrich A3853 at 1:4000), dysbindin-1A and 1C (Hdys764 at
1:800; PA3111 at 1:800–1:1000, or UPenn 329 at 1:200),
dysbindin-1B (UPenn 331 at 1:1000–1:5000), PSD-95 (US
Biological, Swampscott, MA, USA, P9150-10 at 1:1000), and
synaptophysin (Millipore, Billerica, MA, USA, MSB5258 at
1:5000). After exposure to a primary antibody, membranes were
incubated with a horseradish peroxidase-coupled secondary
antibody (HRP-conjugated mouse IgG, GE Healthcare NA931)
for 1 h at room temperature and reacted with the ECL Plus
chemiluminescence system except b-actin blots reacted with a
standard ECL chemiluminescence system (GE Healthcare) to
avoid saturation. Immunoblotting for b-actin as a loading control
was only performed on membranes previously probed for
dysbindin-1 and then stripped with the ECL protocol before
reprobing for b-actin. High-range rainbow molecular weight
markers were used (GE Healthcare RPN756E).
Band densities were quantified with the GS-800 calibrated
densitometer (Bio-Rad) using Quantity One 4.6.3 analysis software
(Bio-Rad). Equivalent band areas across samples were selected
using the volume rectangle tool. The global background
subtraction method was used to obtain the net optical density of
the bands. This raw data was then normalized to total loaded
protein by calculating a ratio of the net optical density of each
dysbindin-1 isoform to that of synaptosomal b-actin. All statistical
analyses were performed on the normalized data. Equivalent
statistical results were found on original and replication experi-
ments run with the same samples, as well as in group-wise analyses
of the data (i.e., all normal cases vs. all schizophrenia cases using
t-tests)
Data analysis
The matched pairs design minimized problems comparing data
across Western blots encountered with between-groups designs
when the number of samples exceeds the number of loading lanes
on a single gel. Samples from both members of a case-control pair
were run side-by-side on the same gel and thus under the same
conditions. While all pairs could not be run on a single gel, our
interest was in a measure we and others (e.g., [83,84]) have found
to be stable across Western blots, namely ratios of the protein level
in a schizophrenia case to that in its matched control. Using b-
actin normalized data, then, the ratio of a dysbindin-1 isoform in a
schizophrenia case to that in its matched control was calculated.
These ratios were log2 transformed so that a zero ratio indicates no
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difference between a case and its control, a negative ratio indicates
a decrease in the case, and a positive ratio indicates an increase in
the case. While the Wilcoxon signed ranks test is commonly used
to analyze differences within matched pairs, log transformation
enables its use to analyze ratio data since the log of a ratio between
two values X/Y = logX2logY. This test was accordingly used to
assess significance of case-control differences in each dysbindin-1
isoform tested.
Unpaired t-tests were used for between-group statistical
comparisons of (a) normal vs. schizophrenia demographic and
postmortem variables and (b) dysbindin-1 isoform levels in the
pSTG and HF of normal cases. Pearson correlation coefficients
were used to test the relationship of case-control differences in one
dysbindin-1 isoform versus those in other such isoforms and to test
the relationship of dysbindin-1 isoform levels in schizophrenia
cases to neuroleptic medication expressed in chlorpromazine
equivalents a month prior to death. The p values reported are two-
tailed; values less than 0.05 were considered significant.
Supporting Information
Figure S1 Characterization of dysbindin-1 antibodies
used in this study. A: Western blots of the same whole tissue
lysates probed with dysbindin-1 antibodies PA3111 (1:800),
Hdys764 (1:800), UPenn 329 (1:200), or UPenn 331 (1:1000).
Lysates were made from samples of the posterior superior
temporal gyrus (pSTG) and caudate nucleus (Cd) of normal
humans. B: Western blots of tagged recombinant dysbindin-1A,
either full length (FL) or the C-terminus region (CTR) alone,
probed with UPenn 329 (1:200) or UPenn 331 (1:5000) with or
without antibody preadsorption by the peptide immunogen. The
FL protein was histidine-tagged mouse dysbindin-1A. The CTR
peptide (the peptide immunogen for Hdys764) consisted of aa
198–351 in human dysbindin-1A tagged with histidine-, serine-,
and thioredoxin. The tagged FL and CTR sequences are
predicted to have molecular weights of 40 and 35 kDa,
respectively, but run 10 kDa higher probably due to the highly
acidic CTR (PI,3.7) as found for other highly acidic proteins [7]
and possibly also due to ubiquitination [6]. C: Western blot
showing that UPenn 331 (1:5000) is highly selective for dysbindin-
1B. It does recognize dysbindin-1A in whole brain lysates in
humans and mice, but has much higher affinity for dysbindin-1B
in humans and recognizes no such isoform in mice, which do not
express a transcript for that isoform [3]. MWM = molecular
weight marker positions.
(TIF)
Figure S2 Specificity of PA3111 verified in tests on
whole tissue lysates from brains of three wild-type (WT)
and three homozygous sandy (Sdy/Sdy) mice. WT mice
express two major dysbindin-1 isoforms (1A and 1C). These
isoforms run at about 50 and 33 kDa; neither is detected in sdy/
sdy mice. Another band at about 26 kDa ({) is seen in WT mice,
but is probably a degradation product of the 33 kDa band. Two
bands marked by asterisks (*) are cross-reacting proteins since they
are just as strong in the sdy/sdy mice lacking dysbindin-1. They
are not seen in samples made from small amounts of tissue (i.e.,
from individual brain areas such as the cerebral cortex, HF, or
cerebellum).
(TIF)
Text S1 Specificity tests on the dysbindin-1 antibodies.
This describes and discusses tests on our dysbindin-1 antibodies
with positive and negative controls.
(DOC)
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